Hip FractureNCT07102732
Modified New Mobility Score - Turkish Version
An observational study of Hip Fracture and Hip Fracture Surgeries, run by Istanbul Rumeli University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this validation and reliability study is to translate the modified version of the New Mobility Score (NMS) into Turkish (NMS-TR), culturally adapt it, and examine its psychometric properties in elderly individuals (aged 65 years and older) with hip fractures. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Hip Fracture, Hip Fracture Surgeries
- How many people
- 120 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 21 Mar 2025to 29 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Voluntary patients aged 65 years and older with a hip fracture
Who may be able to join
- aged 65 years and older
- postoperative hip fracture who were admitted to the Orthopedics and Traumatology Department of Fatih Sultan Mehmet Training and Research Hospital
Who cannot join
- under the age of 65
- Without a hip fracture
- Not being a voluntary participant
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi
Istanbul, Ataşehir, 34752
About this study
Official title: VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF THE MODIFIED NEW MOBILITY SCORE
The goal of this validation and reliability study is to translate the modified version of the New Mobility Score (NMS) into Turkish (NMS-TR), culturally adapt it, and examine its psychometric properties in elderly individuals (aged 65 years and older) with hip fractures.
The main questions it aims to answer are:
Read more
- Is the New Mobility Score a valid and reliable measurement tool for assessing mobility in Turkish individuals with hip fractures?
- Is the New Mobility Score not a valid and reliable measurement tool in this population?
There is no comparison group in this study.
Participants will:
Provide demographic and clinical information. Undergo cognitive assessment using the Mini-Mental State Examination (MMSE). Be evaluated for comorbidity burden using the Charlson Comorbidity Index (CCI). Have their ambulatory function assessed with the Cumulative Ambulation Score (CAS).
- Conditions
- Hip Fracture, Hip Fracture Surgeries
- Keywords
- Hip, Fracture, Ambulation, Outcome Measures, Assessment
- Medical subject headings
- Hip Fractures, Fractures, Bone
What is being measured
The primary outcome is the main question the study is designed to answer.
modified The New Mobility Score
The NMS requires a self-report on the ability to complete walking tasks in different settings, including indoor walking (e.g., within a house), outdoor walking, and walking during shopping. Each item is scored on a scale from 0 to 3 based on the individual's self-reported ability: a score of 0 indicates the individual was unable to complete the task, a score of 1 indicates the individual required assistance from another person to complete the task, a score of 2 indicates the individual completed the task with the aid of a walking aid, and a score of 3 indicates the individual completed the task independently without any walking assistance.
Measured: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
Cumulative Ambulation Score
The Cumulative Ambulation Score assesses four distinct activities (getting out of bed, sitting, and walking) using a three-point ordinal scale ranging from 0 to 2. A score of 0 indicates that the individual is unable to perform the activity despite human assistance and verbal cues; a score of 1 signifies that the activity can be performed with human assistance and/or verbal prompting from one or more individuals; and a score of 2 denotes the ability to perform the activity safely without human assistance or verbal prompting, although the use of a walking aid is permitted. The total score ranges from 0 to 6.
Measured: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
Secondary outcomes (2)
Mini-Mental State Examination
The total score of this test ranges from 0 to 30, with lower scores indicating more pronounced cognitive impairment. In the literature, a cut-off score of 24 is commonly accepted, with scores of 24 or below suggesting a risk of cognitive impairment.
Measured: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
The Charlson Comorbidity Index
The Charlson Comorbidity Index (CCI) is a common tool used to estimate patients' long-term mortality risk. This index plays an important role in assessing health outcomes by measuring the burden of comorbidities that patients have.
Measured: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start21 Mar 2025
- Primary completion25 Jul 2025
- Study completion29 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Hip FractureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Rumeli University
- Sponsor type
- University, hospital or other
- Collaborators
- Istanbul University - Cerrahpasa, Fatih Sultan Mehmet Training and Research Hospital
- Responsible party
- Principal investigator, Ilayda Kayapinar, Istanbul Rumeli University
- Investigators
- İpek YELDAN, PHD PT, Study director, İstanbul University-Cerrahpaşa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07102732
- Sponsor's protocol ID
- 2024/10
- Status last verified
- Dec 2025
- First submitted
- 30 Jul 2025
- Last updated
- 11 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared because participants did not provide explicit consent for data sharing beyond the current study.
Publications
Kristensen MT, Jakobsen TL, Nielsen JW, Jorgensen LM, Nienhuis RJ, Jonsson LR. Cumulated Ambulation Score to evaluate mobility is feasible in geriatric patients and in patients with hip fracture. Dan Med J. 2012 Jul;59(7):A4464.
PubMed 22759844Parker MJ, Palmer CR. A new mobility score for predicting mortality after hip fracture. J Bone Joint Surg Br. 1993 Sep;75(5):797-8. doi: 10.1302/0301-620X.75B5.8376443.
PubMed 8376443
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF THE MODIFIED NEW MOBILITY SCORE
- ClinicalTrials.gov ID
- NCT07102732
- Acronym / sponsor ID
- 2024/10
- Conditions
- Hip Fracture, Hip Fracture Surgeries
- Keywords
- Hip, Fracture, Ambulation, Outcome Measures, Assessment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Istanbul Rumeli UniversityUniversity, hospital or other
- Collaborators
- Istanbul University - Cerrahpasa, Fatih Sultan Mehmet Training and Research Hospital
- Study start
- 21 Mar 2025 (actual)
- Primary completion
- 25 Jul 2025 (actual)
- Study completion
- 29 Jul 2025 (actual)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this validation and reliability study is to translate the modified version of the New Mobility Score (NMS) into Turkish (NMS-TR), culturally adapt it, and examine its psychometric properties in elderly individuals (aged 65 years and older) with hip fractures.
The main questions it aims to answer are:
- Is the New Mobility Score a valid and reliable measurement tool for assessing mobility in Turkish individuals with hip fractures?
- Is the New Mobility Score not a valid and reliable measurement tool in this population?
There is no comparison group in this study.
Participants will:
Provide demographic and clinical information. Undergo cognitive assessment using the Mini-Mental State Examination (MMSE). Be evaluated for comorbidity burden using the Charlson Comorbidity Index (CCI). Have their ambulatory function assessed with the Cumulative Ambulation Score (CAS).
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Voluntary patients aged 65 years and older with a hip fracture
Key inclusion criteria (2 listed)
- aged 65 years and older
- postoperative hip fracture who were admitted to the Orthopedics and Traumatology Department of Fatih Sultan Mehmet Training and Research Hospital
Key exclusion criteria (3 listed)
- under the age of 65
- Without a hip fracture
- Not being a voluntary participant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
modified The New Mobility Score
Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
The NMS requires a self-report on the ability to complete walking tasks in different settings, including indoor walking (e.g., within a house), outdoor walking, and walking during shopping. Each item is scored on a scale from 0 to 3 based on the individual's self-reported ability: a score of 0 indicates the individual was unable to complete the task, a score of 1 indicates the individual required assistance from another person to complete the task, a score of 2 indicates the individual completed the task with the aid of a walking aid, and a score of 3 indicates the individual completed the task independently without any walking assistance.
Cumulative Ambulation Score
Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
The Cumulative Ambulation Score assesses four distinct activities (getting out of bed, sitting, and walking) using a three-point ordinal scale ranging from 0 to 2. A score of 0 indicates that the individual is unable to perform the activity despite human assistance and verbal cues; a score of 1 signifies that the activity can be performed with human assistance and/or verbal prompting from one or more individuals; and a score of 2 denotes the ability to perform the activity safely without human assistance or verbal prompting, although the use of a walking aid is permitted. The total score ranges from 0 to 6.
2 secondary outcomes
Mini-Mental State Examination
Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
The Charlson Comorbidity Index
Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2025.
- Results publication: PubMed 22759844Kristensen MT, Jakobsen TL, Nielsen JW, Jorgensen LM, Nienhuis RJ, Jonsson LR. Cumulated Ambulation Score to evaluate mobility is feasible in geriatric patients and in patients with hip fracture. Dan Med J. 2012 Jul;59(7):A4464.
- Results publication: PubMed 8376443Parker MJ, Palmer CR. A new mobility score for predicting mortality after hip fracture. J Bone Joint Surg Br. 1993 Sep;75(5):797-8. doi: 10.1302/0301-620X.75B5.8376443.
- Individual participant dataSharing planned: No. IPD will not be shared because participants did not provide explicit consent for data sharing beyond the current study.
Related trials for Hip Fracture
Enrolling by invitationObservational study
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
Osteoporosis
Not yet recruitingObservational study
3D-Printed Pelvic Models for Planning Complex Total Hip Arthroplasty
Developmental Dysplasia of the Hip, Acetabular Bone Loss
Recruiting
Monitored Anesthesia Care and Soft Tissue Infiltration With Local Anesthesia Feasibility Trial
Hip Fracture Surgeries, Intertrochanteric Fracture
Not yet recruitingPhase 4
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
Active, not recruitingPhase 2
BDSF Vs DHS With Anterotational Screw in Vertical FNF
Evaluation of BDSF in FNF
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
İpek YELDAN, PHD PT study director
İstanbul University-Cerrahpaşa
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Fracture and Hip Fracture Surgeries, run by Istanbul Rumeli University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
modified The New Mobility Score (time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07102732, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2025.